This video examines a pilot trial that tested stereotactic body radiotherapy plus nephrectomy in patients with renal cell carcinoma.
In this video, Thomas Schwaab, MD, PhD, of Roswell Park Cancer Institute in Buffalo, New York, discusses a pilot trial that tested stereotactic body radiotherapy (SBRT) plus nephrectomy in patients with renal cell carcinoma.
The research, which was published in Clinical Cancer Research, also provides evidence that immunotherapy may be an effective third element to this combination.
Video courtesy of Roswell Park Cancer Institute.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.